Replies to post #303956 on Amarin Corp Plc (AMRN)

[Monk44]

sstyles

There you go making sense again. Love it.

[Number sleven]

sstyles, Thank you for elaborating on what I glossed over. Do you know if Teva is pursuing further legal action? I assume they will. I think you are spot on in your analysis. The risk for generic companies to launch at scale is high. They could be risking bankruptcy over sales of one drug. I didn't think they will do it either. I hope you and I are right.
Sleven,

[postes]

Styles..I think your right...WS should have a PR from AMRN...only silenxet

[Biobillionair]

Lost profits damages could be large enough to have a material impact on the business viability of either Hikma or Dr. Reddy’s.

Legal advice to Hikma from an attorney.

https://www.markmanadvisors.com/blog/2020/10/7/can-amarin-benefit-from-the-gsk-v-teva-decision-regarding-induced-infringement-for-off-label-sales

[golden flyer]

its ironic--thero had absolutely nothing to do with this new impetus to stock price,

[circuitcity]

Very encouraging analysis, and I agree with most of it. Couple thoughts I have are: 1) think Hikma will still launch but not at high volume, they can launch as a min amount just to keep their 6 mos exclusivity; 2) I am less optimistic than you on teva case to be held;!at least their chance getting en banco is better than amrn imo. And I believe that is how street is seeing us. If street share your view, amrn now should be traded at a prior to 3/31 level or even more.

I hope you are right and hope JT will take good advantage of this opportunity and make a reasonable deal.